Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Receivables (2018 - 2024)

Serina Therapeutics' Change in Receivables history spans 7 years, with the latest figure at -$163000.0 for Q1 2024.

  • For Q1 2024, Change in Receivables fell 89.53% year-over-year to -$163000.0; the TTM value through Jun 2024 reached $673000.0, up 332.07%, while the annual FY2023 figure was $554000.0, 2738.1% up from the prior year.
  • Change in Receivables for Q1 2024 was -$163000.0 at Serina Therapeutics, down from $175000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $661000.0 in Q3 2023 and bottomed at -$196000.0 in Q2 2023.
  • The 5-year median for Change in Receivables is -$11000.0 (2020), against an average of $16000.0.
  • The largest annual shift saw Change in Receivables plummeted 3650.0% in 2020 before it soared 6109.09% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $124000.0 in 2020, then tumbled by 99.19% to $1000.0 in 2021, then skyrocketed by 200.0% to $3000.0 in 2022, then skyrocketed by 5733.33% to $175000.0 in 2023, then plummeted by 193.14% to -$163000.0 in 2024.
  • Per Business Quant, the three most recent readings for SER's Change in Receivables are -$163000.0 (Q1 2024), $175000.0 (Q4 2023), and $661000.0 (Q3 2023).